With regards to the biological relevance of TRAIL regulation by NKp46, both proteins are known players in anti-tumor responses (Koch et al., 2013, Seki et al., 2003, Walczak et al., 1999); hence, the concomitant expression of NKp46 and TRAIL is likely to potentiate NK cell direct killing activity against tumors bearing NKp46 ligands and TRAIL receptors. The gene discussed is NCR1; the disease is neoplasm.